Companies / Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc.
CYCNCIK 1755237
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 3, 2021 | Slate Path Capital LP 10% owner | Buy Open-market buy | Common Stock, no par value | $3.00M | +962K +15.52% | 7,157,601 | high |
| Jun 3, 2021 | Hecht Peter M CEO | Buy Open-market buy | Common Stock | $2.70M | +823K +67.22% | 2,047,698 | high |
| May 19, 2023 | Hecht Peter M CEO | Grant Grant or award | Common Stock | $1.95M | +225K +219.76% | 327,385 | low |
| May 5, 2021 | Hecht Peter M CEO | Buy Open-market buy | Common Stock | $1.01M | +398K +75.88% | 922,528 | high |
| May 6, 2021 | Hecht Peter M CEO | Buy Open-market buy | Common Stock | $733.9K | +302K +32.74% | 1,224,528 | high |
| May 4, 2021 | Hecht Peter M CEO | Buy Open-market buy | Common Stock | $687.0K | +300K +133.61% | 524,527 | high |
| Nov 21, 2024 | Slate Path Capital LP 10% owner | Sell Open-market sale | Common Stock, no par value | $555.1K | -358K -100.00% | 0 | medium |
| Mar 25, 2025 | Hecht Peter M CEO | Grant Grant or award | Common Stock | $500.0K | +182K +48.18% | 559,203 | low |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| CYCN | common | 23255M105 |
| CYCN | common | 23255M204 |